{"classes":[{"categories":[{"measurements":[{"comment":"CP-751,871 was safe and well tolerated at dose levels up to 20 mg/kg, and MTD was not achieved.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"The highest dose level at which not more than 1 dose-limiting toxicity (DLT) was observed during Cycle 1 in 6 participants","groups":[{"description":"CP-751,871 0.025, 0.05, 0.1, 0.2, 0.4, 0.8, 1.5, 3 and 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks); CP-751,871 10 and 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG000","title":"CP-751,871 0.025-20 mg/kg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 dose of study drug CP-751,871.","reportingStatus":"POSTED","timeFrame":"Baseline up to Cycle 1 (Week 4 or Week 8)","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mg/kg"}